Skip to content

Study on the role of rectus femoris and visceral fat area in evaluating the progression of diabetic nephropathy

Study on the role of rectus femoris and visceral fat area in evaluating the progression of diabetic nephropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042214
Enrollment
Unknown
Registered
2021-01-15
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Normal albuminuria group:Nil
proteinuria group:Nil
renal insufficiency group:Nil

Sponsors

Shenzhen Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were hospitalized in the Department of Endocrinology, Shenzhen Hospital of Southern Medical University from February 2021 to February 2022, aged 18 years or above, were selected and diagnosed according to the 1999 who diagnostic criteria for diabetes.

Exclusion criteria

Exclusion criteria: 1. Renal diseases caused by other reasons: including primary glomerular or tubular diseases, renal diseases caused by immune abnormalities, renal insufficiency caused by renal perfusion insufficiency, renal vascular diseases, infection and obstructive nephropathy, connective tissue diseases, drug and poison injuries, congenital / genetic diseases, trauma, etc; 2. Other factors affecting glucose and lipid metabolism: hyperthyroidism, hypothyroidism, Cushing's syndrome, hypothalamic and pituitary lesions, long-term use of hormone therapy, etc.; 3. Patients with decreased muscle strength or muscle atrophy caused by other reasons: craniocerebral trauma, tumor, cerebrovascular disease, central and peripheral nervous system inflammation or degeneration injury, bone and joint diseases, poisoning, hypokalemia, congenital / genetic diseases, etc.; 4. Patients with type 1 diabetes, gestational diabetes, diabetic ketoacidosis, hyperosmolar nonketotic coma; 5. Subjects with severe liver disease and heart disease, long-term use of anti-inflammatory drugs, acute or chronic infection; 6. Subjects who are pregnant or plan to be pregnant in the near future; 7. Patients with acute or chronic infectious diseases or cancer; 8. Subjects who could not sign informed consent.

Design outcomes

Primary

MeasureTime frame
cross sectional area of rectus femoris;visceral fat area;Urinary albumin-to-creatinine ratio;24-hour urinary albumin;Estimated glomerular filtration rate;

Countries

China

Contacts

Public ContactLingling Xu

Shenzhen Hospital of Southern Medical University

lucylingl@126.com+86 13538838066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026